There is no single number that PSA “should” be after radiation for prostate cancer. Instead, the goal is for PSA to fall steadily over months to years until it reaches its lowest point, called the nadir. In large studies of patients treated with radiation alone, the median nadir lands around 0.4 to 0.6 ng/mL, though patients who also receive hormone therapy often drop far lower. What matters most is not hitting an exact target but watching the trajectory: a PSA that keeps declining or stays flat is reassuring, while a sustained rise of 2 ng/mL above whatever your lowest point was is the standard signal that something may need attention.
How PSA Falls After Radiation
Unlike surgery, which removes the prostate entirely and can drive PSA to essentially zero within weeks, radiation kills cancer cells gradually. The prostate gland remains in place, and normal prostate tissue continues to produce some PSA. That means PSA drops slowly, sometimes over a period of years, before settling at its lowest value. In a study of over 4,800 men treated with external beam radiation, the median time to reach nadir was about 18 months, but some patients did not bottom out for several years afterward. Men whose treatment was ultimately successful tended to reach a lower nadir (around 0.4 ng/mL) and took slightly longer to get there (about 21 months) compared with men whose cancer later returned, who had a higher median nadir of 1.0 ng/mL reached at around 15 months.1International Journal of Radiation Oncology, Biology, Physics. Significance of PSA Nadir Following Radiotherapy Given for Prostate Cancer
The slow decline can feel unsettling. You might get a PSA reading at three months that still seems high, and that is completely expected. Radiation-induced cell death continues for months after your last treatment session, and the PSA curve reflects that gradual process. Your doctor will typically check PSA every three to six months in the first few years and then less frequently once it stabilizes.
Why Your Nadir Matters More Than Any Fixed Number
The nadir is the single strongest predictor of long-term cancer control after radiation, more powerful than pre-treatment PSA or tumor grade. Early research showed that men whose PSA dropped to 0.5 ng/mL or below had roughly 95% disease-free survival at five years and 84% at ten years, while every patient whose nadir stayed above 1.0 ng/mL eventually experienced a recurrence.2PubMed. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer Later work with larger patient groups confirmed the trend and added nuance: eight-year biochemical disease-free rates were about 80% for men who reached a nadir at or below 0.2 ng/mL, compared with roughly 36% for those whose nadir landed between 1.1 and 2.0 ng/mL.3International Journal of Radiation Oncology, Biology, Physics. Postirradiation Prostate Specific Antigen Nadir Level Predicts Freedom From Biochemical Failure and Distant Metastasis in Patients With Localized Prostate Cancer
The takeaway is straightforward: the lower your PSA goes and stays, the better your chances. But there is no magic cutoff that separates “safe” from “unsafe.” A nadir of 0.8 ng/mL is not necessarily a failure, and a nadir of 0.3 ng/mL does not guarantee cure. The number is best understood as a probability slider, with lower values associated with progressively better odds.
The Standard Definition of Biochemical Failure
The widely used benchmark for declaring that radiation has not controlled the cancer comes from the 2005 Phoenix Consensus Conference. The rule: a PSA rise of 2 ng/mL or more above your personal nadir counts as biochemical failure. If your lowest PSA was 0.5 ng/mL, a confirmed reading of 2.5 ng/mL or higher would trigger concern. The date of failure is marked “at call,” meaning the day the qualifying PSA was drawn, not backdated to some earlier point.4PubMed. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
This definition applies whether you received radiation alone or radiation combined with hormone therapy, and it covers external beam radiation as well as brachytherapy. It replaced an older definition that required three consecutive PSA rises, which was more confusing and harder to apply consistently. The “nadir plus 2” rule is simple enough to follow on your own: just know your lowest reading, and flag any result that has climbed 2 ng/mL above it.
One thing to keep in mind is that biochemical failure does not automatically mean the cancer is life-threatening or even clinically significant. Some men with a slowly rising PSA after radiation live for decades without symptoms. What the definition does is create a standardized trigger for further investigation, potentially including imaging or additional treatment.
How Hormone Therapy Changes the Picture
If you received androgen deprivation therapy (ADT) alongside radiation, your PSA numbers will look very different from someone treated with radiation alone. Hormone therapy suppresses testosterone, which in turn suppresses PSA production from both normal and cancerous prostate tissue. In trials comparing the two approaches, the median PSA at six months was 2.2 ng/mL for men who received radiation alone but just 0.1 ng/mL for those who also had short- or long-term hormone therapy. Only about 2% of men in the radiation-only group reached an ultra-low nadir below 0.1 ng/mL, compared with 16 to 23% of those who had added ADT.5ASCO Daily News. PSA Nadir 6 Months After Radiotherapy Is Strongly Prognostic of Long-Term Survival in Patients With Localized Prostate Cancer
A large study looking specifically at patients who had radiation plus ADT found that the vast majority (about 93%) reached a nadir of 0.1 ng/mL or below, with most getting there within five to six months. By the 12-month mark, roughly 86% of those patients had a PSA at or below 0.1 ng/mL.6PubMed Central. Detectable prostate‐specific antigen after radiotherapy for clinically localized prostate cancer So if you had hormone therapy, do not be alarmed by an extraordinarily low PSA. It is expected. The more useful question becomes what happens to your PSA after hormone therapy ends and testosterone recovers, which can take months to a year or more. A PSA that stays low even after testosterone returns is a stronger sign of durable cancer control.
The PSA Bounce and Why It Causes So Much Anxiety
Perhaps the most stressful part of PSA monitoring after radiation is the bounce: a temporary rise in PSA that happens in the absence of cancer recurrence. A meta-analysis pooling data from more than 26,000 patients found that about 31% experienced a bounce, with an average amplitude of 1.3 ng/mL. The bounce typically showed up around 18 months after treatment.7PubMed Central. Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis A separate systematic review of nearly 9,000 patients reported a very similar bounce rate of about 30.5%.8PubMed. Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis
The bounce is thought to result from inflammation, delayed prostate cell death, or immune-related activity in the treated tissue. It is not well understood, but it is clearly common. Younger men seem to be more prone to it. The type of radiation also plays a role: a study of patients treated with MR-guided stereotactic body radiation therapy (SBRT) found a bounce rate of about 25%, with a median onset at 11 months. In that group, the vast majority of bounces (about 86%) occurred within the first six months after treatment.9PubMed. Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique
The critical point: a bounce usually resolves on its own. Your doctor will likely recommend waiting and rechecking rather than immediately pursuing invasive tests or treatment. The 2 ng/mL Phoenix threshold was partly designed to avoid overreacting to bounces, since most bounces are smaller than that. But some bounces can be quite dramatic.
Telling a Bounce Apart from a Real Recurrence
Distinguishing a harmless bounce from the beginning of a true recurrence is one of the harder judgment calls in prostate cancer care. A study of brachytherapy patients found substantial overlap between the two: bounces reached PSA levels as high as 12.6 ng/mL, and in some patients it took more than five years for PSA to decline back below 0.5 ng/mL after a bounce. However, one factor stood out as a reliable differentiator: timing. A benign bounce was not seen after 36 months post-treatment. A PSA rise that begins within the first three years is more likely to be a bounce, while a rise starting later is more worrisome.10PubMed Central. Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy
Other patterns can help inform the conversation with your doctor. Men who bounced tended to be younger, had lower pre-treatment PSA levels, and showed a faster rate of PSA doubling during the rise. Men whose cancer was truly returning tended to have a slower, more sustained climb. None of these features is definitive on its own, and the overlap is real, which is why the usual approach is watchful patience combined with serial PSA checks rather than an immediate leap to biopsy or salvage treatment at the first sign of a rise.
How Different Types of Radiation Affect PSA
Not all radiation techniques produce the same PSA trajectory. Higher-dose approaches like stereotactic body radiation therapy (SBRT) and high-dose-rate (HDR) brachytherapy tend to drive PSA lower than conventional intensity-modulated radiation therapy (IMRT). A comparison study found that SBRT and HDR brachytherapy produced significantly lower nadirs than IMRT, with PSA continuing to decline slowly even beyond three years after treatment. With IMRT, the PSA decline tended to level off after about 1,000 days.11PubMed. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer
This matters because if you were treated with SBRT or brachytherapy, your expected nadir may be lower than the general figures quoted in older studies that were based mostly on conventional external beam radiation. Conversely, a nadir of 0.6 ng/mL after IMRT may carry the same prognostic meaning as a somewhat lower value after brachytherapy. The context of how you were treated shapes what your numbers mean.
When Undetectable PSA Is the Goal
Reaching an undetectable PSA after radiation is the most favorable outcome, though it is more commonly discussed in the context of salvage radiation, which is radiation given after a failed surgery. In a study of salvage radiation patients, those who achieved an undetectable PSA had a 75% rate of biochemical control at 3.5 years, compared with only 18% for those whose PSA remained detectable. Undetectable PSA was the strongest independent predictor of cure, outweighing tumor stage, surgical margin status, and other factors.12PubMed. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome–results of a retrospective study
A more recent study confirmed this finding with longer follow-up: patients with a post-salvage-radiation PSA nadir below 0.1 ng/mL had about 78% biochemical progression-free survival at five years, compared with just 16% for those whose PSA stayed detectable.13Radiotherapy and Oncology. Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy In brachytherapy specifically, one group reported that none of their patients who reached an undetectable PSA went on to have a subsequent rise.14Journal of Clinical Oncology. Undetectable PSA level following prostate brachytherapy
For primary radiation (radiation as first-line treatment with the prostate still in place), reaching truly undetectable PSA is less common because remaining normal prostate tissue continues to produce small amounts. Getting close to undetectable is excellent, but do not be discouraged if your PSA plateaus at 0.2 or 0.3 ng/mL after primary radiation. That is still a very good result.
What Happens When PSA Rises and Imaging Comes Into Play
If your PSA does meet the criteria for biochemical failure, the next step is usually advanced imaging to figure out where the cancer might be. PSMA PET scans have transformed this process. In a prospective trial of 635 men with biochemical recurrence after various treatments, the scan detected cancer in about 75% of patients at a median PSA of 2.1 ng/mL. Detection rates climbed steeply with PSA: from 38% when PSA was between 0.2 and 0.5 ng/mL, to 57% at 0.5 to 0.9 ng/mL, to 84% or higher once PSA passed 1.0 ng/mL.15The ASCO Post. When to Consider a PSMA PET Scan After Radical Prostatectomy and Salvage Radiation for Prostate Cancer Separate data suggest that PSMA PET can detect recurrence at PSA levels as low as 0.22 ng/mL in some cases, though sensitivity at such low levels is still limited.16Journal of Nuclear Medicine. PSMA PET/CT study post initial radiation treatment of prostate cancer with biochemical recurrence
The imaging results shape treatment decisions. If the scan shows cancer confined to a small area (oligometastatic disease), targeted treatments may be offered. If it reveals widespread disease, systemic therapy like hormones or chemotherapy typically takes priority. In either case, the PSA value at which imaging is triggered matters: scanning too early (at very low PSA) often produces inconclusive results, while waiting until PSA is quite high may miss the window for curative-intent treatment.
Salvage Treatment After Radiation Failure
When biochemical failure is confirmed and imaging localizes the disease, several salvage options exist. For men whose cancer appears confined to the prostate or pelvis, salvage radical prostatectomy is one approach. Retrospective and prospective data show overall survival of roughly 84 to 95% at five years and 52 to 77% at ten years following salvage surgery.17PubMed Central. The Role of Salvage Radical Prostatectomy in Patients with Radiation-Resistant Prostate Cancer Other salvage options include cryotherapy, high-intensity focused ultrasound (HIFU), and re-irradiation, though these are generally considered only at specialized centers and carry higher complication risks than primary treatment.
The PSA level at the time salvage treatment begins has prognostic significance. Lower PSA at the time of intervention is generally associated with better outcomes. This is one reason doctors pay such close attention to PSA trends rather than waiting for dramatic elevations before acting.
Living with PSA Monitoring
The emotional weight of repeated PSA tests is real. Research following prostate cancer patients for five years after diagnosis found that about 28% were classified as having high anxiety before treatment, and while average anxiety levels decreased post-treatment, men treated with radiation reported somewhat higher rates of depression than those treated with surgery. Around 27% of radiation-treated men reported clinically significant depression during follow-up, compared with about 20% in the general population. Mental health did improve at the six-month mark across all groups, but the recurring cycle of testing and waiting for results, sometimes called “PSA anxiety” or “scanxiety,” remains a common experience.
Knowing the typical patterns described above can help. If you understand that a bounce is common, that your PSA may not reach its nadir for two or three years, and that a single elevated reading does not necessarily mean recurrence, each lab visit may feel less like a verdict. Many cancer centers now offer survivorship programs that address the psychological side of long-term monitoring alongside the medical surveillance itself.